135 related articles for article (PubMed ID: 38775501)
1. Preoperative cancer antigen-125 levels as a predictor of recurrence in early-stage endometrial cancer.
Erturk A; Korkmaz E; Arslantas Z; Bekdemir S; Erturk NK
Rev Assoc Med Bras (1992); 2024; 70(5):e20231115. PubMed ID: 38775501
[TBL] [Abstract][Full Text] [Related]
2. The Value of Preoperative CA 125 Levels in Prediction of Myometrial Invasion in Patients with Early-stage Endometrioid- type Endometrial Cancer.
Atguden Z; Yildiz A; Aksut H; Yalcin SE; Yalcin Y; Uysal D; Yetimalar H
Asian Pac J Cancer Prev; 2016; 17(2):497-501. PubMed ID: 26925634
[TBL] [Abstract][Full Text] [Related]
3. What is the predictive value of preoperative CA 125 level on the survival rate of type 1 endometrial cancer?
Yilmaz Baran Ş; Alemdaroğlu S; Doğan Durdağ G; Yüksel Şimşek S; Bolat F; Köse F; Çelik H
Turk J Med Sci; 2021 Feb; 51(1):335-341. PubMed ID: 32979897
[TBL] [Abstract][Full Text] [Related]
4. Value of circulating tumor cells positive for thyroid transcription factor-1 (TTF-1) to predict recurrence and survival rates for endometrial carcinoma.
Zhang Y; Qu X; Qu PP
J BUON; 2016; 21(6):1491-1495. PubMed ID: 28039713
[TBL] [Abstract][Full Text] [Related]
5. Preoperative serum CA 125 level as a predictor for metastasis and survival in endometrioid endometrial cancer.
Pinar Cilesiz Goksedef B; Gorgen H; Baran SY; Api M; Cetin A
J Obstet Gynaecol Can; 2011 Aug; 33(8):844-850. PubMed ID: 21846440
[TBL] [Abstract][Full Text] [Related]
6. [Clinicopathologic and survival analysis of synchronous primary endometrial and ovarian cancer].
Wang Y; Yu M; Yang JX; Cao DY; Zhang Y; Shen K; You Y
Zhonghua Fu Chan Ke Za Zhi; 2018 Dec; 53(12):816-822. PubMed ID: 30585019
[No Abstract] [Full Text] [Related]
7. Use of preoperative serum CA-125 levels for prediction of lymph node metastasis and prognosis in endometrial cancer.
Chung HH; Kim JW; Park NH; Song YS; Kang SB; Lee HP
Acta Obstet Gynecol Scand; 2006; 85(12):1501-5. PubMed ID: 17260229
[TBL] [Abstract][Full Text] [Related]
8. CTNNB1 (beta-catenin) mutation identifies low grade, early stage endometrial cancer patients at increased risk of recurrence.
Kurnit KC; Kim GN; Fellman BM; Urbauer DL; Mills GB; Zhang W; Broaddus RR
Mod Pathol; 2017 Jul; 30(7):1032-1041. PubMed ID: 28281553
[TBL] [Abstract][Full Text] [Related]
9. An intensive follow-up does not change survival of patients with clinical stage I endometrial cancer.
Gadducci A; Cosio S; Fanucchi A; Cristofani R; Genazzani AR
Anticancer Res; 2000; 20(3B):1977-84. PubMed ID: 10928137
[TBL] [Abstract][Full Text] [Related]
10. HE4 is superior to CA125 in the detection of recurrent disease in high-risk endometrial cancer patients.
Abbink K; Zusterzeel PL; Geurts-Moespot AJ; Herwaarden AEV; Pijnenborg JM; Sweep FC; Massuger LF
Tumour Biol; 2018 Feb; 40(2):1010428318757103. PubMed ID: 29463191
[TBL] [Abstract][Full Text] [Related]
11. The preoperative serum CA125 can predict the lymph node metastasis in endometrioid-type endometrial cancer.
Ünsal M; Kimyon Comert G; Karalok A; Basaran D; Turkmen O; Boyraz G; Tasci T; Koc S; Boran N; Tulunay G; Turan T
Ginekol Pol; 2018; 89(11):599-606. PubMed ID: 30508211
[TBL] [Abstract][Full Text] [Related]
12. Ten years of experience with endometrial cancer treatment in a single Brazilian institution: Patient characteristics and outcomes.
Anton C; Kleine RT; Mayerhoff E; Diz MDPE; Freitas D; Carvalho HA; Carvalho JPM; Silva ASE; Genta MLND; Silva ALFE; Salim RC; Aranha A; Lopez RVM; Carvalho FM; Baracat EC; Carvalho JP
PLoS One; 2020; 15(3):e0229543. PubMed ID: 32134921
[TBL] [Abstract][Full Text] [Related]
13. Predictive factors for prolonged survival in recurrent endometrial carcinoma: Implications for follow-up protocol.
Otsuka I; Uno M; Wakabayashi A; Kameda S; Udagawa H; Kubota T
Gynecol Oncol; 2010 Dec; 119(3):506-10. PubMed ID: 20837356
[TBL] [Abstract][Full Text] [Related]
14. HE4 and CA125 as preoperative risk stratifiers for lymph node metastasis in endometrioid carcinoma of the endometrium: A retrospective study in a cohort with histological proof of lymph node status.
O'Toole SA; Huang Y; Norris L; Power Foley M; Shireen R; McDonald S; Kamran W; Ibrahim N; Ward M; Thompson C; Murphy C; D'Arcy T; Farah N; Heron E; O'Leary JJ; Abu Saadeh F; Gleeson N
Gynecol Oncol; 2021 Feb; 160(2):514-519. PubMed ID: 33213897
[TBL] [Abstract][Full Text] [Related]
15. Preoperative thrombocytosis as a prognostic factor in endometrioid-type endometrial carcinoma.
Abu-Zaid A; Alsabban M; Abuzaid M; AlOmar O; Salem H; Al-Badawi IA
Ann Saudi Med; 2017; 37(5):393-400. PubMed ID: 28988254
[TBL] [Abstract][Full Text] [Related]
16. Comparable outcome between endometrioid and non-endometrioid tumors in patients with early-stage high-grade endometrial cancer.
Reynaers EA; Ezendam NP; Pijnenborg JM
J Surg Oncol; 2015 May; 111(6):790-4. PubMed ID: 25900897
[TBL] [Abstract][Full Text] [Related]
17. Unique prognostic features of grade 3 endometrioid endometrial carcinoma: Findings from 101 consecutive cases at a Japanese tertiary cancer center.
Kato MK; Yoshida H; Uehara T; Uno M; Ishikawa M; Miyasaka N; Kato T
Taiwan J Obstet Gynecol; 2021 Mar; 60(2):238-244. PubMed ID: 33678322
[TBL] [Abstract][Full Text] [Related]
18. Preoperative serum CA125: a useful marker for surgical management of endometrial cancer.
Jiang T; Huang L; Zhang S
BMC Cancer; 2015 May; 15():396. PubMed ID: 25964114
[TBL] [Abstract][Full Text] [Related]
19. [The importance of HE4 in differential diagnosis of endometrial cancer].
Minář L; Klabenešová I; Jandáková E
Ceska Gynekol; 2015 Aug; 80(4):256-63. PubMed ID: 26265413
[TBL] [Abstract][Full Text] [Related]
20. Adult Comorbidity Evaluation 27 score as a predictor of survival in endometrial cancer patients.
Binder PS; Peipert JF; Kallogjeri D; Brooks RA; Massad LS; Mutch DG; Powell MA; Thaker PH; McCourt CK
Am J Obstet Gynecol; 2016 Dec; 215(6):766.e1-766.e9. PubMed ID: 27457116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
